Medical Xpress November 19, 2024
More than half of all American adults, almost 137 million people, could be candidates for the blockbuster GLP-1 drug semaglutide, a new analysis finds.
Sold as Ozempic for treating diabetes and Wegovy to spur weight loss, the medication could be indicated for those two purposes or to help prevent heart disease, explained a team led by Dr. Dhruv Kazi, of Beth Israel Deaconess Medical Center in Boston.
The medicines are made by Novo Nordisk and can cost nearly a thousand dollars per month, however, so it’s not clear who might pay for all those tens of millions of prescriptions.
Right now, insurance companies typically only cover the cost of semaglutide if a doctor indicates its use against type 2 diabetes.
...Today's Sponsors
Today's Sponsor